Risk of Myeloma Still Small Despite Newly Revealed Gene Mutations
In the largest study to date, researchers from The Institute of Cancer Research in London identified eight new gene mutations increasing the risk of developing…
News
EU OKs Extended Indication for Amgen’s Myeloma Drug Kyprolis
Global biotech firm Amgen has announced that the European Commission (EC) approved a variation to the marketing authorization for Kyprolis (carfilzomib) to be used in combination with…
Multiple Myeloma Treatment Outcomes May Improve with ‘Next-Generation Drug Candidates’, Review Says
Advances in the molecular understanding of multiple myeloma (MM) onset and disease development have enabled the production of effective drugs, such as bortezomib,thalidomide, and lenalidomide,…
One Multiple Myeloma Induction Therapy Stands Out in Test for Transplant-eligible Patients
Results from a clinical trial support the use of a specific combination drug induction therapy over another three-drug treatment in multiple myeloma patients who are eligible…
Relapsed/Refractory Multiple Myeloma Drug by Takeda Receives Negative Opinion from EMA
Takeda Pharmaceutical Company Limited has recently received a negative opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use…
Multiple Myeloma Among Topics in APSHO Educational Series for Healthcare Workers
The Advanced Practitioners Society for Hematology and Oncology (APSHO) is presenting a series of live continuing medical education (CME) meetings, titled the “APSHO Regional Lecture…
New Data from Key Trial of Kyprolis to Treat Advanced Multiple Myeloma Shows Benefits
Amgen reported findings from a post-hoc analysis of the pivotal Phase 3 ASPIRE clinical trial, highlighting the continued benefits of carfilzomib (Kyprolis), a second-generation proteasome inhibitor, plus a standard…
Positive Results from Phase 3 Trial of Combo Therapy for Multiple Myeloma Presented at ASCO 2016
Researchers from Janssen Research & Development presented promising interim results from the Phase 3 MMY3004 (CASTOR) clinical trial, assessing the immunotherapy drug daratumumab (Darzalex) against standard of care…
Study Reveals Multiple Myeloma Treatment Disparities Between Caucasian, African-American Patients
Celgene Corporation recently presented a study comparing overall survival, treatment patterns, and healthcare costs between Caucasian (white-skinned) and African-American Medicare beneficiaries who were diagnosed with multiple…
Founder of Multiple Myeloma Research Foundation Named Co-Chair of Harvard’s Kraft Precision Medicine Accelerator
The Multiple Myeloma Research Foundation (MMRF) has announced that its founder, Kathy Giusti, has been appointed faculty co-chair of the Harvard Business School (HBS)…
